Business
Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System
MADISON, Wis., Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™
About this update from Accuray Incorporated
[{"type":"text","content":"MADISON, Wis., Jan. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company's Radixact SynC™ System and CyberKnife® S7™ System have been approved by the Chinese National Medical Products Administration (NMPA). With these approvals medical care teams can provide patients in China the most advanced Accuray radiation therapy solutions. The CyberKnife S7 System is the latest generation CyberKnife platform and the introduction of the Radixact SynC System marks the first approval in the country for the ClearRT® kVCT imaging and Synchrony® real-time adaptive delivery technology on the Radixact System.\n\n \n \n \n \n \n \n\n \n\"We couldn't be more pleased about the timing of these approvals that come on the heels of the introduction of our Tomo C System, developed for the unique needs of the largest segment of the market in China,\" said Suzanne Winter, president and CEO of Accuray.\nContinued Ms. Winter, \"I am thrilled with the customer adoption of the Tomo C System since its approval last year. Now with our latest CyberKnife S7 and Radixact SynC Systems, the Accuray teams in China can offer a powerful product portfolio to address clinicians' varied requirements. Currently, the number of people needing radiotherapy treatments in China far outweighs the capacity for treatment. In fact, it is estimated that approximately 2,000 systems will be needed over the next five years1. These approvals further advance our growth strategy of expanding patient access by offering compelling and unique solutions to enable more people to receive treatment with our potentially life-saving technology.\"\nThe Radixact SynC and CyberKnife S7 Systems are designed to improve the radiation treatment experience while making high precision care available for more patients.\nRadixact SynC System: Cancer Treatment that Revolves Around the PatientThe Radixact SynC System's helical design enables the delivery of precise doses of radiation continuously from multiple 360-degree rotations around the patient, providing greater control of the radiation dose so it conforms precisely to the tumor and minimizes dose to healthy tissue.\nThe Radixact SynC System is currently the only helical delivery device in China with Synchrony real-time target tracking and correction technology. The addition of Synchrony to the Radixact System is d...